John R. Eckardt

Statistics

Publications

Citations

3.5K

H-Index

Active since

1993

Affiliations

The University of Texas at San Antonio Health Science Center(Current)

Brooke Army Medical Center

Joint Base San Antonio

St. John's University

Arog Pharmaceuticals (United States)

John R. Eckardt is an author at The University of Texas at San Antonio Health Science Center specializing in pharmacology, medicine, and chemotherapy.

Publications per year

1993–2017

Publications

Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer

John R. Eckardt, Joachim von Pawel, Jean-Louis Pujol et al. · Journal of Clinical Oncology · 2007 · 384 citations

Medicine, Oncology, Pharmacology +13

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

Mace L. Rothenberg, John R. Eckardt, John G. Kuhn et al. · Journal of Clinical Oncology · 1996 · 352 citations

Medicine, Oncology, Pharmacology +13

Phase I and pharmacokinetic trial of weekly CPT-11.

Mace L. Rothenberg, John G. Kuhn, Howard A. Burris et al. · Journal of Clinical Oncology · 1993 · 303 citations

Medicine, Oncology, Pharmacology +16

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.

David Rinaldi, Howard A. Burris, F. Andrew Dorr et al. · Journal of Clinical Oncology · 1995 · 152 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer

John R. Eckardt, Joachim von Pawel, Zsolt Pápai et al. · Journal of Clinical Oncology · 2006 · 147 citations · Full text

Medicine, Oncology, Pharmacology +10

1–5 of 55